Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Equity Average (2016 - 2025)

IGC Pharma has reported Equity Average over the past 15 years, most recently at $7.1 million for Q3 2025.

  • Quarterly Equity Average fell 7.12% to $7.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Sep 2025, down 7.12% year-over-year, with the annual reading at $6.8 million for FY2025, 38.6% down from the prior year.
  • Equity Average was $7.1 million for Q3 2025 at IGC Pharma, up from $6.2 million in the prior quarter.
  • Over five years, Equity Average peaked at $32.3 million in Q2 2021 and troughed at $6.2 million in Q2 2025.
  • The 5-year median for Equity Average is $14.1 million (2023), against an average of $16.7 million.
  • Year-over-year, Equity Average surged 34.75% in 2021 and then tumbled 50.72% in 2024.
  • A 5-year view of Equity Average shows it stood at $30.4 million in 2021, then plummeted by 36.67% to $19.2 million in 2022, then crashed by 39.81% to $11.6 million in 2023, then plummeted by 41.1% to $6.8 million in 2024, then rose by 3.92% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Equity Average are $7.1 million (Q3 2025), $6.2 million (Q2 2025), and $6.3 million (Q1 2025).